Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00577642 · OUTCOME

Number of Participants With Urinary NTX Levels Less Than or Equal to 50nmol/mmol Cr

Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates · Source last updated 2017-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
6 months

What was measured

Number of participants with urinary NTX levels less than or equal to 50 nmol/mmol creatinine (Cr) for the duration of study followup, following a single dose Zoledronic Acid (Zoledronate) 4mg IV over at least 15 minutes (or dose corrected for creatinine clearance x1). Dose administration was followed by Aminobisphosphonates (aBP) treatment cessation during study period.

Groups in this outcome

Zoledronic Acid

Single dose Zoledronic Acid (Zoledronate) 4mg IV over at least 15 minutes (or dose corrected for creatinine clearance x1) followed by Aminobisphosphonates (aBP) treatment cessation during study period.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Zoledronic Acid29

Reported measurements

Source class 1

NTX level ≤ 50 nmol/mmol Cr

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Zoledronic Acid28Not reportedNot reportedNot reportedNot reported

NTX level > 50 nmol/mmol Cr

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Zoledronic Acid1Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Description
    Paired t-tests were used to compare differences of NTX cytokine levels at study entry versus end-of-study.
    group Ids
    1. OG000
    non Inferiority Comment
    single group
    non Inferiority Type
    OTHER
    p Value
    <0.05
    statistical Method
    t-test, 1 sided
Complete source fields
analyses
  1. group Description
    Paired t-tests were used to compare differences of NTX cytokine levels at study entry versus end-of-study.
    group Ids
    1. OG000
    non Inferiority Comment
    single group
    non Inferiority Type
    OTHER
    p Value
    <0.05
    statistical Method
    t-test, 1 sided
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        28
      title
      NTX level ≤ 50 nmol/mmol Cr
    2. measurements
      1. group Id
        OG000
        value
        1
      title
      NTX level > 50 nmol/mmol Cr
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    units
    Participants
description
Number of participants with urinary NTX levels less than or equal to 50 nmol/mmol creatinine (Cr) for the duration of study followup, following a single dose Zoledronic Acid (Zoledronate) 4mg IV over at least 15 minutes (or dose corrected for creatinine clearance x1). Dose administration was followed by Aminobisphosphonates (aBP) treatment cessation during study period.
groups
  1. description
    Single dose Zoledronic Acid (Zoledronate) 4mg IV over at least 15 minutes (or dose corrected for creatinine clearance x1) followed by Aminobisphosphonates (aBP) treatment cessation during study period.
    id
    OG000
    title
    Zoledronic Acid
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
6 months
title
Number of Participants With Urinary NTX Levels Less Than or Equal to 50nmol/mmol Cr
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice